Editorial Advisory Board Member, Harvard Health Publishing Popular GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) typically cause people to eat less
It's typically prescribed for adults who haven't achieved adequate blood sugar control with diet and exercise alone
Answer : The major players in the GLP-1 analogues market include Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim, Pfizer, Amgen, Roche, Zealand Pharma, Structure Therapeutics, Viking Therapeutics, Hangzhou Sciwind Biosciences, Fudan University, Eccogene, Medtronic, Merck & Co., AbbVie, Bayer AG, Teva Pharmaceutical Industries Ltd., and Boehringer Ingelheim
J Clin Endocrinol Metab 94(2):603608
Clinically tested, European innovation